WHO Maturity Level 3 and Device Self-Assessment in Ethiopia

1. Key takeaways

Over the past two years, Ethiopia’s regulatory system crossed a threshold that changes how the market should be read. On 29 September 2025, EFDA announced that it had reached World Health Organization (WHO) regulatory maturity level 3 (ML3) for medicines: the ninth country in Africa and the first in the Intergovernmental Authority on Development (IGAD) region. Subsequently, on 28 July 2026, it launched its first medical device regulatory system self-assessment (WHO GBT+ medical device module). For companies, the two milestones mean different things and must not be conflated: ML3 is a completed conclusion on the medicines side, while the device self-assessment is a process still under way. External statements, project documents and budget justifications should treat the two as separate facts, because blending them creates a credibility risk with both regulators and internal stakeholders who later discover that the device side has no maturity rating at all. The distinction also matters for timing: conclusions on the medicines side can be cited today, while anything said about the device side must remain a statement about a process that has started, not a result.

2. Legal basis

3. Expert insights

Insight 1: the GBT assesses the regulatory system and contains more than 250 indicators.

The WHO Global Benchmarking Tool applies more than 250 indicators across the complete regulatory cycle, from approval, inspection and quality control testing to post-market surveillance and governance. ML3 means the regulatory system is stable and functions well, not that technical requirements are lenient. What companies should expect accordingly is more traceable processes and more consistent decisions, not a lower bar. Planning applications on the assumption that maturity status reduces evidentiary demands is a misreading of what the benchmark measures.

Insight 2: the gap between the medicines ML3 and the device self-assessment is exactly where current uncertainty lies.

The medicines side has completed its assessment and reached ML3, while the device side only launched its self-assessment on 28 July 2026. This gap explains why Ethiopia’s device guideline system, including EFDA/GDL/097 Version 002, the EFDA-GDL-090 vigilance guideline and the EFDA_GDL_037 field safety corrective action guideline, was issued intensively within 2026: completing the guideline set is precisely the preparation for the device system assessment. The guideline wave should therefore be read as system-building, not as administrative housekeeping.

Insight 3: a self-assessment is a self-assessment, and does not equal a maturity conclusion.

In the WHO GBT process, self-benchmarking is an internal baseline step taken before formal assessment. Until the official assessment conclusion is published, no conclusion exists that Ethiopian device regulation has reached any maturity level. External communication and internal project approvals should use the formulation that a self-assessment has been launched, never that the device side has reached ML3, and contract documents should avoid committing to regulatory outcomes that have not been rated.

Insight 4: the self-assessment will act backwards on dossiers companies have already submitted.

If the self-assessment identifies system gaps and drives guideline revisions, dossiers previously prepared under older guidelines may need to be completed at re-registration or change filings. Treating the self-assessment as the starting point of a recurring system iteration, rather than as a one-off event, is closer to actual practice, and a version ledger of guidelines is the cheapest insurance against being surprised by the next iteration.

Insight 5: the most tangible benefit of ML3 is the possibility of regional mutual recognition.

The EFDA Director-General noted in a World Bank feature that 8 countries that have reached ML3 have signed agreements to mutually recognise each other’s decisions. Such recognition currently concentrates on the medicines side; whether and when a comparable mechanism forms for devices depends on the outcome of the self-assessment and the subsequent formal assessment, and it should not be used as a project justification at this stage.

4. Practical recommendations

1. Keep external statements strictly separated: say only that medicines have reached ML3 and that the device self-assessment has been launched; never merge the two into a device ML3 claim.
2. Self-check system documents against the GBT framework: prioritise completing the record chains for post-market surveillance, vigilance, market surveillance and recalls.
3. Build a guideline version ledger: record the versions and effective dates of EFDA/GDL/097, EFDA-GDL-090, EFDA_GDL_037 and other guidelines, and assess impact whenever a revision appears.
4. Track the self-assessment inside the regulatory intelligence process: the formal assessment conclusion after the self-assessment may alter reliance pathways and documentation requirements.
5. Do not bet on regional mutual recognition: no device-side mechanism has taken shape, so schedule submissions country by country.

5. Verification checklist

• □ Date of medicines ML3 recorded: 29 September 2025 (ninth in Africa, first in IGAD)
• □ Date of device system self-assessment launch recorded: 28 July 2026
• □ External statements do not apply ML3 to devices
• □ System documents self-checked against the WHO GBT framework of more than 250 indicators
• □ Version ledger of EFDA device guidelines established
• □ Self-assessment tracking integrated into the regulatory intelligence process
• □ Submission schedule does not depend on regional mutual recognition

Regulatory information verified as of 29 October 2026. The ML3 result and the device self-assessment launch date listed in this article follow EFDA official announcements and the current WHO GBT documentation; this article draws no conclusion on the device-side maturity level before an official assessment result is published.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.